Last reviewed · How we verify
Standardized Allergenic Extract, Cat Hair
This allergenic extract contains cat hair proteins that trigger controlled immune sensitization to desensitize patients to cat allergens through repeated exposure.
This allergenic extract contains cat hair proteins that trigger controlled immune sensitization to desensitize patients to cat allergens through repeated exposure. Used for Cat allergy (allergic rhinitis and/or asthma triggered by cat allergen exposure).
At a glance
| Generic name | Standardized Allergenic Extract, Cat Hair |
|---|---|
| Also known as | Standardized Cat Hair Allergenic Extract |
| Sponsor | Antigen Laboratories, Inc. |
| Drug class | Allergenic extract |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Standardized cat hair allergenic extract is used in allergen immunotherapy (AIT) to gradually desensitize the immune system to cat allergens. By administering increasing doses of the allergen, the therapy promotes a shift from IgE-mediated responses toward IgG-blocking antibodies and regulatory T cell responses, reducing allergic symptoms upon natural exposure to cats.
Approved indications
- Cat allergy (allergic rhinitis and/or asthma triggered by cat allergen exposure)
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions (urticaria, angioedema, bronchospasm)
- Anaphylaxis
Key clinical trials
- Allergenic Extract Standardized Cat Hair AP in an Allergic Rhinitis Model. (NA)
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation (PHASE1)
- Anakinra as a Rescue Treatment for Allergic Inflammation (PHASE1, PHASE2)
- Imaging Study of the Lungs During an Allergic Asthma Attack (NA)
- T Cell Effector and Regulatory Mechanisms in Asthma (PHASE1)
- Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma (PHASE1)
- Phase 2 Study in Adults Sensitized to Cat (PHASE2)
- Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: